HT-0712

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C25H31NO3
Molecular Weight	393.5185
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(OC2CCCC2)C=C(C=C1)[C@H]3CNC(=O)[C@H](CC4=CC(C)=CC=C4)C3

InChI

InChIKey=ABEJDMOBAFLQNJ-NHCUHLMSSA-N

InChI=1S/C25H31NO3/c1-17-6-5-7-18(12-17)13-20-14-21(16-26-25(20)27)19-10-11-23(28-2)24(15-19)29-22-8-3-4-9-22/h5-7,10-12,15,20-22H,3-4,8-9,13-14,16H2,1-2H3,(H,26,27)/t20-,21-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C25H31NO3
Molecular Weight	393.5185
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17823313 | http://dartneuroscience.com/DrugPrograms.php

Inflazyme Pharmaceuticals initially developed HT-0712 as a phosphodiesterase IV (PDE4) inhibitor with anti-inflammatory properties. Now the rights on this drug are wholly owned by Dart NeuroScience. January 2015, Dart NeuroScience completed a phase II trial of HT-0712 for the memory disorders, where were evaluated the efficacy in improving memory and cognitive performance.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Phosphodiesterase 4 52 Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17823313	Inhibitor 8297

PubMed

Title	Date	PubMed
A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4.	2003 Sep 2	12930888
A novel phosphodiesterase type 4 inhibitor, HT-0712, enhances rehabilitation-dependent motor recovery and cortical reorganization after focal cortical ischemia.	2007 Nov-Dec	17823313
Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking?	2008 Oct	18660832
The PDE4 inhibitor HT-0712 improves hippocampus-dependent memory in aged mice.	2014 Dec	24964813
Investigational phosphodiesterase inhibitors in phase I and phase II clinical trials for Alzheimer's disease.	2017 Sep	28772081

Sample Use Guides

In Vivo Use Guide

HT-0712 capsules (50mg) administered once daily.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 05:00:26 UTC 2023` Edited by `admin` on `Sat Dec 16 05:00:26 UTC 2023`
Record UNII	2O43FXG9IG
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

HT-0712

Common Name

English

OX-914

Code

English

BLX-028914

Code

English

IPL-455903

Code

English

2-PIPERIDINONE, 5-(3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL)-3-((3-METHYLPHENYL)METHYL)-, (3S,5S)-

Systematic Name

English

Code System Code Type Description

WIKIPEDIA

HT-0712